RTP Mobile Logo
Submitted by web@researchtop... on Tue, 04/10/2018 - 14:55
DOU118

Interview with Jeffrey Weber, MD, PhD

Track 1: COMBI-AD: Results from a Phase III trial of adjuvant dabrafenib and trametinib for resected Stage III BRAF-mutated melanoma
Track 2: CheckMate 238: Efficacy and safety of adjuvant nivolumab versus ipilimumab in resected Stage III/IV melanoma
Track 3: Potential benefit of targeted therapy in the adjuvant versus the metastatic setting
Track 4: Choosing between dabrafenib/trametinib and nivolumab as adjuvant therapy for BRAF-mutant melanoma
Track 5: Therapeutic options for patients who experience disease progression on adjuvant treatment
Track 6: Risk of disease relapse with adjuvant immunotherapy versus targeted therapy for patients with node-positive disease
Track 7: Emerging data with checkpoint inhibitors added to BRAF/MEK inhibitor combinations for metastatic melanoma
Track 8: Long-term survival rates for patients with metastatic melanoma after treatment with targeted agents or immunotherapy
Track 9: Checkpoint inhibitor-associated immune-related adverse events
Track 10: Choice of nivolumab and ipilimumab versus either therapy alone for newly diagnosed BRAF wild-type metastatic melanoma
Track 11: Role of PD-L1 expression as a predictive marker of response to immune checkpoint inhibitors
Track 12: Biologic rationale for the addition of HDAC inhibitors to immunotherapy
Track 13: Activity and tolerability of the IDO inhibitor epacadostat in combination with anti-PD-1 antibodies in melanoma
Track 14: Efficacy and safety profiles of the BRAF/MEK inhibitor combinations dabrafenib/trametinib, vemurafenib/cobimetinib and encorafenib/binimetinib for BRAF-mutant melanoma
Track 15: Association of the diversity and composition of the gut microbiome with response to anti-PD-1 blockade in patients with metastatic melanoma
Track 16: Ongoing trials of immunotherapy combinations in patients with melanoma refractory to immune checkpoint inhibitors
Track 17: Case: A 72-year-old man with basal cell carcinoma (BCC) achieves a very good partial response to the hedgehog inhibitor vismodegib
Track 18: Efficacy and tolerability of the hedgehog inhibitors vismodegib and sonidegib
Track 19: Monitoring and management of immune-related adverse events associated with immune checkpoint inhibitors
Track 20: Case: A 37-year-old man with Stage IIIC resected melanoma discontinues adjuvant nivolumab after 9 months due to a stress fracture of the left tibial plateau
Track 21: Role of chimeric antigen receptor T-cell therapy in melanoma
Track 22: Case: A 45-year-old man with recurrent BRAF wild-type Stage IV melanoma and scleroderma achieves a complete response to pembrolizumab after disease progression on multiple therapies
Track 23: Use of immune checkpoint inhibitors in patients with preexisting autoimmune diseases

Interview with Keith T Flaherty, MD

Track 1: Effects of novel therapies on the long-term outcomes of patients with metastatic melanoma
Track 2: Survival of patients with metastatic melanoma who receive immunotherapy compared to targeted therapy
Track 3: Selection of targeted agents versus immunotherapy in the front-line setting for patients with BRAF mutation-positive melanoma
Track 4: Effect of PD-L1 expression on response to immune checkpoint inhibitors
Track 5: Comparison of the efficacy and safety of combination therapy versus monotherapy with immune checkpoint inhibitors
Track 6: Duration of immunotherapy and targeted therapies to achieve optimal clinical benefit
Track 7: Correlation between tumor mutational burden and response to immune checkpoint inhibitors
Track 8: Activity and tolerability of BRAF/MEK inhibitors in combination with anti-PD-1/PD-L1 antibodies
Track 9: Association between the gut microbiome and response to anti-PD-1 antibody-based therapy in metastatic melanoma
Track 10: Effect of disease burden and type of response on outcomes of patients with metastatic melanoma
Track 11: Potential implications of results of the COMBI-AD and CheckMate 238 trials for adjuvant decision-making for patients with resected Stage III/IV melanoma
Track 12: Comparison of the mechanisms of action, activity and safety profiles of encorafenib/binimetinib, dabrafenib/trametinib and vemurafenib/cobimetinib for BRAF-mutant melanoma
Track 13: Selection of first-line therapy for patients with BRAF-mutant metastatic melanoma
Track 14: Ongoing trials of MEK inhibitors with or without anti-PD-1/PD-L1 antibodies in NRAS-mutated melanoma
Track 15: Rationale for the investigation of immune checkpoint inhibitors in combination with MEK inhibitors
Track 16: Mechanism of action and activity of the cancer stemness inhibitor napabucasin
Track 17: Choice of vismodegib versus sonidegib for advanced BCC
Track 18: Dose modifications and treatment holidays to mitigate the side effects associated with hedgehog inhibitors
Track 19: Case: A 72-year-old woman who presents with a rapidly enlarging subcutaneous nodule on her right arm is diagnosed with Merkel cell carcinoma
Track 20: Pathophysiology of Merkel cell carcinoma and rationale for the use of anti-PD-1/PD-L1 antibodies
Track 21: Incidence and clinical presentation of Merkel cell carcinoma
Track 22: Neoadjuvant therapy for melanoma
Track 23: Case: A 21-year-old woman with node-positive, BRAF V600E mutation-positive Stage III melanoma receives dabrafenib/trametinib after disease progression on talimogene laherparepvec and anti-PD-1/anti-CTLA-4 therapy

Interview with Adil Daud, MD

Track 1: Incidence and spectrum of immune-related adverse events associated with immune checkpoint inhibitors
Track 2: Perspective on the utility of immune checkpoint inhibitors in patients with preexisting autoimmune diseases
Track 3: Case: A 35-year-old man with Stage III melanoma and a history of Guillain-Barré syndrome develops diabetes after receiving adjuvant pembrolizumab
Track 4: Viewpoint on the use of immune checkpoint inhibitors or targeted therapy in the adjuvant setting
Track 5: Hepatic and dermatologic side effects associated with immunotherapy
Track 6: Management of brain metastases in patients with melanoma
Track 7: Approach to single-agent versus combination treatment with immune checkpoint inhibitors as first-line therapy for metastatic melanoma
Track 8: Effect of the gut microflora on response to immunotherapy
Track 9: Emerging data with immunotherapy combinations in patients with melanoma
Track 10: Biology of Merkel cell carcinoma and implications for treatment with anti-PD-1/PD-L1 antibodies
Track 11: Benefits and risks of adjuvant nivolumab versus dabrafenib/trametinib for BRAF-mutated melanoma
Track 12: Case: A 47-year-old man with previously treated BRAF mutation-positive metastatic melanoma receives vemurafenib/cobimetinib
Track 13: Indirect comparison of the activity and tolerability profiles of BRAF/MEK inhibitor combinations (dabrafenib/trametinib, vemurafenib/cobimetinib, encorafenib/binimetinib)
Track 14: Clinical outcomes for patients with metastatic uveal melanoma treated with anti-PD-1/PD-L1 antibodies
Track 15: Targeting NRAS mutations with CDK4/6 inhibitors in patients with melanoma
Track 16: Case: A 58-year-old man with metastatic BCC experiences a good response to vismodegib but discontinues treatment due to dysgeusia
Track 17: Incidence and management of KIT-mutated melanoma

Interview with Jason J Luke, MD

Track 1: Results of the Phase I/II ECHO-202/KEYNOTE-037 trial of the IDO inhibitor epacadostat in combination with pembrolizumab in advanced melanoma
Track 2: Mechanism of action and safety profile of epacadostat alone or in combination with an immune checkpoint inhibitor
Track 3: Emerging role of LAG-3 and TIM-3 inhibition in immune checkpoint blockade strategies
Track 4: ADVISE: A planned Phase I adaptive study to match patients with solid tumors to various immunotherapy combinations based on biomarker assessment
Track 5: Diagnostic comparison of CT scans and colonoscopy for immune-related colitis in patients with ipilimumab-treated advanced melanoma
Track 6: Underlying pathobiology leading to immune-related adverse events in patients receiving immunotherapy
Track 7: Activity of immune checkpoint inhibitors and targeted therapies in patients with advanced melanoma and brain metastases
Track 8: Role of radiation therapy in the treatment algorithm for patients with melanoma and brain metastases
Track 9: Risk factors, incidence and mortality rates of melanoma and nonmelanoma skin cancers
Track 10: ONTRAC: Results of a Phase III trial of nicotinamide for nonmelanoma skin cancer chemoprevention
Track 11: Pathophysiology of BCC
Track 12: Role of the hedgehog signaling pathway inhibitors in BCC
Track 13: Side-effect profiles of hedgehog inhibitors
Track 14: Case: A 62-year-old man receives vismodegib for locally recurrent, unresectable BCC
Track 15: Vismodegib-associated side effects
Track 16: Epidemiology and biology of Merkel cell carcinoma
Track 17: Management of Merkel cell carcinoma
Track 18: Response to PD-1/PD-L1 blockade in Merkel cell carcinoma
Track 19: Case: A 61-year-old man with metastatic Merkel cell carcinoma
Track 20: Activity and tolerability of anti-PD-1/anti-CTLA-4 combination therapy for Merkel cell carcinoma
Track 21: Epidemiology, etiology and therapeutic options for squamous cell carcinoma of the skin
 
FACULTY
 
Jeffrey Weber, MD, PhD
Deputy Director
Laura and Isaac Perlmutter Cancer Center
Professor of Medicine
NYU Langone Medical Center
New York, New York
 
Keith T Flaherty, MD
Director
Henri and Belinda Termeer Center for Targeted Therapies
Massachusetts General Hospital
Cancer Center
Professor, Harvard Medical School
Director of Developmental Therapeutics
Boston, Massachusetts
 
Adil Daud, MD
Professor of Medicine
University of California, San Francisco
San Francisco, California
 
Jason J Luke, MD
Assistant Professor of Medicine
The University of Chicago
Chicago, Illinois
 
EDITOR
 
Neil Love, MD
Research To Practice
Miami, Florida